Table 3. Phase 2 VEGF Trials.

	Henry et al. (45) VIVA	Hedman et al. (47) KAT	Kastrup et al. (46) Euroinject One
Patients	Stable angina, “no-option” CAD	Stable CAD undergoing PCI	Severe, stable angina; “no-option” CAD
Therapy	Recombinant human VEGF	Ad or PL VEGF	Plasmid VEGF
Duration of follow-up	60 days, 120 days	6 months	3 months
Primary end point	Δ ETT at 60 days	Minimal lumen diameter, % stenosis	Δ Myocardial perfusion
Secondary end points	Δ ETT, angina, and myocardial perfusion at day 120	Myocardial perfusion, exercise tolerance,  incidence of new cardiac events,  revascularization, functional class	Safety, wall motion, LVEF, angina
Treatment groups	High-dose (n = 59) Low-dose (n = 56) Placebo (n = 63)	Adv (n = 37) PL (n = 28) Placebo (n = 38)	VEGF-A165 (n = 40) Placebo (n = 40)
Dosage	High-dose: 50 ng/kg per min IC for 20 min† Low-dose: 17 ng/kg per min IC for 20 min†	Adv: 2 × 1010 PFU IC PL: 2,000 μg IC	VEGF-A165: 0.5 mg
Findings	↓ in angina class at day 120 in high-dose  group compared with placebo*;  no benefit in ΔETT	↑ in perfusion at 6 months compared  with baseline in Ad group*; no  differences among groups	Improved regional wall motion in VEGF  group compared with placebo*

^*p ≤ 0.05.

^†Followed by 4-h infusions on days 3, 6, and 9.

Adv = adenovirus vector; IC = intracoronary; PCI = percutaneous coronary intervention; PFU = plaque-forming unit; PL = plasmid liposome; VEGF = vascular endothelial growth factor; other abbreviations as in Table 2.